Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zynamite S is a proprietary, **water-soluble extract of Mangifera indica (mango) leaf**, standardized to contain 60% mangiferin as its main bioactive compound. Developed as a next-generation, **enhanced-bioavailability version of Zynamite**, it was specifically engineered to overcome the poor solubility and low bioavailability of standard mangiferin preparations. Zynamite S has been clinically shown to rapidly improve cognitive domains such as processing speed, attention, working memory, and executive function, with effects observed within 30 minutes of a single dose and lasting up to 5 hours. Mechanistic studies attribute efficacy largely to partial inhibition of catechol-O-methyltransferase (COMT), increasing dopamine levels in the prefrontal cortex, as well as possible acetylcholinesterase (AChE) inhibition, which could potentiate cholinergic neurotransmission. Unlike stimulant products, Zynamite S exerts these benefits with no effect on heart rate or blood pressure. It also demonstrates **meaningful improvement in mood and reduction of negative emotional states**, making it a dual-action nootropic for both cognitive and emotional performance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zynamite S.